Author

B. Bhargava

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Research Focus:host-pathogen & immune response· 7 Organism:human· 5 Organism:mouse· 2 Assay:proteomics· 1

Frequent Co-Authors

N. Gupta· 7 shared P. Abraham· 7 shared S. Panda· 7 shared D. Y. Patil· 5 shared G. Deshpande· 4 shared G. Sapkal· 4 shared P. Yadav· 4 shared R. R. Sahay· 4 shared

Activity by Year

2021-2021 · peak 7/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersMicrobiology

N. Gupta

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Neutralization of Delta variant with sera of Covishield vaccinees and COVID-19 recovered vaccinated individuals

G. Sapkal, P. D. Yadav, R. R. Sahay, G. Deshpande, N. Gupta, D. A. Nyayanit, D. Y. Patil, S. Kumar, P. Abraham, S. Panda, B. Bhargava

This study evaluates immune response in Covishield vaccinated and recovered individuals against the Delta variant, finding higher protection in breakthrough cases and recovered individuals compared to single or double vaccinated groups.

bioRxiv · Jul 1, 2021Microbiology

Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152

P. D. Yadav, G. Sapkal, R. Ella, R. R. Sahay, D. A. Nyayanit, D. Y. Patil, G. Deshpande, A. M. Shete, N. Gupta, V. K. Mohan, P. Abraham, S. Panda, B. Bhargava

This study assesses the neutralization efficacy of sera from COVID-19 recovered cases and BBV152 vaccinees against SARS-CoV-2 variants B.1.351 and B.1.617.2, showing reduced titers but still protective responses.

bioRxiv · Jun 5, 2021 · PreprintMicrobiology

Isolation of SARS-CoV-2 B.1.1.28.2 P2 variant and pathogenicity comparison with D614G variant in hamster model

P. Yadav, S. Mohandas, P. Sarkale, D. Nyayanit, A. Shete, R. Sahay, V. Potdar, S. Baradkar, N. Gupta, G. Sapkal, P. Abraham, S. Panda, B. Bhargava

The paper isolates the SARS-CoV-2 B.1.1.28.2 (P.2) variant from travelers and compares its pathogenicity to the D614G variant in hamsters, finding it more severe and with reduced neutralization.

bioRxiv · May 24, 2021Microbiology

Neutralization potential of Covishield vaccinated individuals sera against B.1.617.1

P. Yadav, G. N. Sapkal, P. Abraham, G. Deshpande, D. Nyayanit, D. Y. Patil, N. Gupta, R. R. Sahay, A. Shete, S. Kumar, S. Panda, B. Bhargava

This study compares neutralizing antibody responses in Covishield-vaccinated individuals and COVID-19 recovered subjects against B.1 and B.1.617.1 variants, finding higher neutralization in recovered subjects.

bioRxiv · May 12, 2021Immunology

SARS CoV-2 variant B.1.617.1 is highly pathogenic in hamsters than B.1 variant

P. D. Yadav, S. Mohandas, A. M. Shete, D. A. Nyayanit, N. Gupta, D. Y. Patil, G. N. Sapkal, V. Potdar, M. Kadam, A. kumar, S. Kumar, D. Suryavanshi, C. S. Mote, P. Abraham, S. Panda, B. Bhargava

This study compares the pathogenicity of SARS-CoV-2 variants B.1 and B.1.617.1 in hamsters, finding B.1.617.1 causes greater body weight loss, higher viral load, and more severe lung lesions.

bioRxiv · May 5, 2021 · PreprintMicrobiology

Neutralization of B.1.1.28 P2 variant with sera of natural SARS-CoV-2 infection and recipients of BBV152 vaccine

G. Sapkal, P. Yadav, R. Ella, P. Abraham, D. Patil, N. Gupta, S. Panda, K. M. V, B. Bhargava

This study evaluates the neutralizing efficacy of B.1.1.28.2 variant against sera from natural infection and BBV152 vaccine recipients, showing reduced neutralization compared to D614G.

bioRxiv · Apr 30, 2021 · PreprintMicrobiology

Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees

P. Yadav, G. N. Sapkal, P. Abraham, R. Ella, G. Deshpande, D. Y. Patil, D. Nyayanit, N. Gupta, R. R. Sahay, A. M. Shete, S. Panda, B. Bhargava, V. K. Mohan

The paper assesses the neutralizing ability of sera from BBV152 vaccinees and convalescent COVID-19 patients against B.1.617 variants.

bioRxiv · Apr 23, 2021Immunology